anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention identifies the total nucleotide sequence of a novel oncogene from human, which is directly involved in such a cancerization mechanism as for cervical cancer induced by HPV infection of cervical epithelial cell and the amino acid sequence of an oncogenic protein encoded thereby, and to provide a full-length polynucleotide encoding a peptide chain of the oncogenic protein derived from the novel oncogene, which can be used for recombinant production of the oncogenic protein, and the peptide chain of the oncogenic protein produded recombinantly therewith. Specifically, the present invention provides a novel oncogene polynucleotide from human involving development of cervical cancer, comprising a nucleotide sequence encoding an amino acid sequence of SEQ. ID. No.1, particularly a polynucleotide of the nucleotide sequence of SEQ. ID. No.2.
This trial is for patients with resected pancreatic adenocarcinoma who have concluded adjuvant therapy or were deemed unable to receive adjuvant therapy with an elevated CA19-9 or node positive or margin positive disease. CA 19-9 elevation is defined as two levels \> the institutional upper limit of normal (ULN) taken at least 2 weeks apart. These levels should be measured after adjuvant therapy has concluded or upon the decision that adjuvant therapy will not be offered. Patients will be randomized to one of two arms. Subjects enrolled due to node positive disease or R1 resection must be able to undergo randomization within 3 months of finishing adjuvant therapy or the decision that they are unable to take adjuvant therapy. Patients enrolling due to CA19-9 elevation can enroll any time after adjuvant therapy has completed. Arm A, the treatment arm, will be started on CC-486. Arm B, the control arm, will receive no additional therapy. In both arms, CA19-9 will be followed and CT scans (or MRI, if clinically indicated) will be done every three months. When patients have visible disease recurrence on imaging, CC-486 will be stopped and both groups will start first-line chemotherapy.
PCT No. PCT/EP91/01017 Sec. 371 Date Nov. 30, 1992 Sec. 102(e) Date Nov. 30, 1992 PCT Filed Jun. 3, 1991 PCT Pub. No. WO91/18917 PCT Pub. Date Dec. 12, 1991.The invention includes compounds of the following formula   <IMAGE>   where A and B either A and B form an additional double bond and D is a hydrogen atom or B and D form an additional double bond and A is a hydrogen atom and the other variables are as defined in the specification. Also disclosed is a process of making the compounds and a process of using the compounds to make compounds of the following formula   <IMAGE>   where the variables are defined in the specification. These compounds are useful as antigestigens.
An edible dry-powder formulation of a film coating for pharmaceuticals and confectionaries using gum acacia as a low-cost film former is provided. A  cellulosic polymer such as hydroxypropyl methylcellulose is used in addition to the gum acacia. A plasticizer such as propylene glycol is also added. The resulting formulation is a dry, free flowing powder that can be put into solution and applied to a tablet or other substrate without an extended waiting period. The resulting film coating is clear, shiny, durable and extremely economical. Because the formulation is a dry powder, it has along shelf life and low shipping costs.
Based on the limited available information, the acute symptoms of levodopa/dopa decarboxylase inhibitor overdosage can be expected to arise from dopaminergic overstimulation. Doses of a few grams may result in CNS disturbances, with an increasing likelihood of cardiovascular disturbance (e.g., hypotension, tachycardia) and more severe psychiatric problems at higher doses. An isolated report of rhabdomyolysis and another of transient renal insufficiency suggest that levodopa overdosage may give rise to systemic complications, secondary to dopaminergic overstimulation.

Monitor patients and provide supportive care. Patients should receive electrocardiographic monitoring for the development of arrhythmias; if needed, appropriate antiarrhythmic therapy should be given. The possibility that the patient may have taken other drugs, increasing the risk of drug interactions (especially catechol-structured drugs) should be taken into consideration.
Breast cancer remains a significant public health issue, often resulting in severe side effects such as neutropenia, highlighting the need for reliable predictors of clinical outcomes. This study aimed to evaluate the predictive value of body composition measures for mortality, recurrence, and chemotherapy-induced neutropenia in patients with breast cancer following surgery and chemotherapy. We retrospectively analyzed 85 breast cancer patients who underwent surgery and chemotherapy between 2006 and 2016. Body composition was assessed using computed tomography (CT) or positron emission tomography (PET) at diagnosis and three years and five years post-diagnosis. Metrics included skeletal muscle area (SMA), skeletal muscle index (SMI), subcutaneous adipose tissue area (SAT), and visceral adipose tissue area (VAT). Longitudinal analysis revealed a decrease in muscle mass (P < 0.001 for both SMA and SMI) and nonsignificant changes in fat mass (P = 0.449 for SAT and P = 0.798 for VAT). A lower SMI at diagnosis was significantly associated with increased mortality (P = 0.019) and a higher incidence of grade 4 neutropenia (P = 0.008). There was no significant association between SMI at diagnosis and recurrence (P = 0.691). No associations were found between body composition measurements during the follow-up period and the clinical outcomes. Lower skeletal muscle mass at diagnosis is strongly associated with higher mortality and chemotherapy-induced complications in patients with breast cancer, highlighting the potential of readily available imaging techniques as valuable predictors of clinical outcomes.
Azacycloalcane derivatives having general formula (I) wherein R¿1? and R¿2? represent a hydrogen atom, an alkyl group or a phenyl group, or R¿1? and R¿2? form together an oxo group, R¿3? is a hydrogen atom or an alkyl group, or R¿3? forms a methylene group, R¿4? is an aromatic group or, when R¿3? forms a methylene group, R¿4? is a phenylene group of which a carbon atom is bound to Y and another carbon atom adjacent to the former carbon atom is bound to said methylene group, R¿5? is either a group OR¿7? where R¿7? is a hydrogen atom or a benzyl group, or a group N¿4?-methyl-piperazinyl, or else a group NHR¿8? wherein R¿8? is a hydroxyl, pyridinylmethyl or phenylmethyl group, A is an optionally substituted aromatic cycle, n is 1 or 2, X is CH, O or N, and Y is CH¿2?, O or S, their preparation process and their applications in therapy.
The invention provides a new medicine which has distinguished curative effect and cures coronary heart disease for the market. The invention belongs to the technical field of the Chinese traditional patent medicine. The taking of the medicine is secure, the effect is taken fast, the medicine source is broad, the cost is low, and the production process is simple. The recipe of the invention comprises lycopus herb, cape jasmine, dragon's blood resin, rhubarb, safflower, frankincense, common myrrh tree, red sage root, peach kernel, balloonflower, astragalus root, gleditschia horrida (also honeylocust fruit), rhodiola root, achyranthes root, red peony root, root-bark of peony, forsythia fruit, earth worm and licorice, etc. The pathogenesis of the coronary heart disease comprises blood stasis and blockage. The treatment method comprises blood circulation promotion and blood stasis dissipation, Qi invigoration and blood promotion, and phlegm resolving and orifice opening, namely, the blood is promoted to be smooth in blood vessels. The drugs administration of the recipe of the invention can be ascended or descended, the drug can be used for the cold property and the heat property, the drug has the functions of invigoration as well as the purge, blood circulation promoting as well as blood arresting. The invention is restricted mutually, opposite and united, and accords with the thing development law. The quality of the  blood of dragon resin is extremely important. The blood circulation promotion and blood stasis dissipation (comprising blood stasis and phlegm stasis) is a key point. The medicine has the remarkable curative effect to cerebral thrombosis and the traumatic injury, and also has a certain curative effect to the avascular necrosis of femoral head.
271,492. Chemische Fabric auf Actien vorm. E. Schering. May 20, 1926, [Convention date]. Medicines for internal use.-Substances similar to the hormones extracted from animal germ glands, placenta &c., are obtained from vegetable organisms by extraction with an organic solvent, concentrating the extract and treating with water or a water-miscible organic solvent and finally extracting the solution or suspension so obtained, or the residue from its evaporation, with ether. According to examples (1) rhubarb or apples are extracted with ethyl or methyl alcohol and the solution, after repeated concentration and treatment with alcohol to precipitate impurities, is evaporated to dryness and the residue extracted with ether; (2) lily of the valley buds or potatoes are comminuted, dried, and extracted with ether in a Soxhlet apparatus and the residue of the ethereal solution is suspended in water and the suspension extracted with ether. Specifications 6019/08 and 18414/12 are referred to. The Specification, as open to inspection under Sect. 91 (3) (a) describes also the treatment of cherries according to examples (1) above, includes further examples according to which (1) parsley root is extracted with methyl alcohol, the solution is evaporated to dryness and the residue dissolved in water and the aqueous solution extracted with ether; (2) yeast free from albumen, obtained by the process of Buchner and Gruber, is extracted with ether, the solution evaporated, the residue extracted with acetone, and after evaporation of the acetone the residue extracted with ether; (3) and a mixture of moist yeast and water is extracted by pressure and the juice extracted with ether, evaporated and purified by repeated solution in ether and acetone: and relates generally to the treatment of plants by any method similar to those employed for obtaining the hormones from animal organs. This subject-matter does not appear in the Specification as accepted.
A system (SY) for determining a relative importance of each of a plurality of image features (F n ) of a vascular medical image impacting an overall diagnostic metric computed for the image from an automatically-generated diagnostic rule. A medical image database (MIDB) includes a plurality of vascular medical images (M 1..k ). A rule generating unit (RGU) analyzes the plurality of vascular medical images and automatically generates at least one diagnostic rule corresponding to a common diagnosis of a subset of the plurality of vascular medical images based on a plurality of image features common to the subset of vascular medical images. An image providing unit (IPU) provides a current vascular medical image (CVMI) including the plurality of image features. A diagnostic metric computation unit (DMCU) computes an overall diagnostic metric for the current vascular medical image by applying the at least one automatically-generated diagnostic rule to the current vascular medical image. A decision propagation unit (DPU) identifies, in the current vascular medical image, the relative importance of each of the plurality of image features on the computed overall diagnostic metric.
Although coronary heart disease (CHD) treatment guidelines recognize obesity as a major modifiable risk factor,2 nearly half of all CHD patients are obese and the current standard of care fails to implement evidence-based obesity treatment for this high-risk population. The efficacy of exercise-based cardiac rehabilitation for improving exercise capacity and CHD risk factors is markedly blunted in CHD patients with obesity. Current programs largely focus on nutrient intake and produce minimal weight loss, on average. Our data show that despite appropriate exercise prescription and adherence, only 22% of CHD patients with obesity lose even the minimum recommended body weight over a 3-month program. These findings indicate that targeting reductions in caloric intake is needed to optimize outcomes in these patients and suggest that current programs are too short to produce adequate weight loss and ensure the necessary behavioral adaptations for long-term maintenance. Randomization to diet-induced weight loss in combination with aerobic exercise improves exercise capacity, quality of life, and CHD risk factors more than exercise alone and reduces long-term mortality in overweight and obese adults. The primary goal of this study is to determine the feasibility of adding a 6-month behavioral weight loss intervention to exercise-based cardiac rehabilitation.
All 15 GCA patients will undergo 68-Ga HA-DOTATATE PET/CT imaging at baseline, in addition to FDG PET/CTA (as part of standard of care). DOTATATE PET/CT imaging will be repeated at 6 months follow-up.
Abdominal adhesions manifests following abdominal infections triggered by intestinal fistulas. The severity of such adhesions depends on the extent of fiber deposition and peritoneal fibrinolysis following peritoneal injury, which may be influenced by sustained inflammation within the abdominal cavity. In this regard, the visceral-to-subcutaneous fat area (VFA/SFA) ratio has been implicated as a potential marker of inflammation. This study aimed to explore the relationship between VFA/SFA and abdominal adhesions. This multicenter study was conducted across four tertiary institutions and involved patients who had undergone definitive surgery (DS) for intestinal fistula from January 2009 and October 2023. The presence of abdominal adhesions was determined intraoperatively. VFA/SFA was investigated as a potential risk factor for severe adhesions. The study comprised 414 patients with a median age of 50 [interquartile range (IQR) 35-66] years and a median body mass index of 20.0 (IQR 19.2-22.4) kg/m2, including 231 males with a median VFA/SFA of 1.0 (IQR 0.7-1.2) and 183 females a median VFA/SFA of 0.8 (0.6-1.1). VFA/SFA was associated with severe abdominal adhesions in males [odds ratio (OR) = 3.34, 95% CI 1.14-9.80, p = 0.03] and females (OR = 2.99, 95% CI 1.05-8.53, p = 0.04). J-shaped association between VFA/SFA ratio and severe adhesions was revealed in both sex. The increasing trend can be revealed when OR more than 0.8, and 0.6 in males and females respectively. Preoperative VFA/SFA demonstrates predictive value for statues of severe abdominal adhesions in DS for anastomotic fistula after small intestine resection.
BACKGROUND: The use of radiological approaches in forensic investigations is rapidly emerging as an alternative to traditional autopsies. Here, we present the experience of the Sicilian and Calabrian forensic medical departments over the past five years, highlighting the application of PMCT to support autopsies in cases involving gunshot wound victims.
MATERIALS AND METHODS: From January 2020 to March 2024, thirty cadavers who died from gunshot wounds underwent total body PMCT examinations followed by autopsies. The examinations included multi-planar and 3D reconstructions. Data collected for each subject included gender, age, mode of death, type of weapon, number of shots, body sites affected, and presence of retained bullets. A team of two radiologists and two forensic physicians evaluated the images and compared them with the autopsy findings.
CONCLUSION: PMCT and 3D reconstruction enabled evaluation of entry wounds, fracture margins, injury sites, fragments, and anatomical trajectories. The results from PMCT were compared with autopsy findings in terms of entry wounds, wound channels, foreign bodies, organ and skeletal injuries, and causes of death. PMCT showed concordance with autopsy findings in determining the cause of death in all cases. The speed, non-invasiveness, and ability to manipulate and reconstruct data make PMCT an ideal technique for supporting forensic investigations and autopsies. PMCT is highly reliable for accurately identifying lethal wounds and determining the cause of death. It excels at tracking wound paths, distinguishing entrance and exit wounds, locating retained bullets, and detecting fragmentation and dispersion of ballistic components.
Methods and compositions are provided for recombinant DNA production of Factor VIIIC and truncated derivatives thereof. Based on amino acid sequences, probes are developed for isolating messenger RNA, cDNA and/or chromosomal DNA encoding for Factor VIIIC. The Factor VIIIC gene in its entirety, a fragment thereof, or a cDNA is then used for expression of Factor VIIIC in a host. The bacteriophage lambda FVIII23D containing the 14.43kb EcoRI fragment was deposited at the A.T.C.C. on Jan. 4, 1984 and given Accession No. 40094. Also, the vector pSVF8-200 was deposited at the A.T.C.C. on July 17, 1985 and given Accession No. 40190.
The intervention drug, meloxicam is safe medicine which is used to treat pain or inflammation caused by osteoarthritis or rheumatoid arthritis in adults and children who are at least 2 years old. It may also be used for purposes not listed in the medication guide. It will be taken once a daily with a dose of 0.125 mg/kg/day (high-dose group) or 0.06 mg/kg/day (low-dose group). After 6 months of medication, the maintenance will be decided by the comparison of liver stiffness score before and after the intervention.
Patients receive FOLFOX every 2 weeks plus placebo every day for 12 treatments (24 weeks). Each 2-week period is called a cycle. FOLFOX includes oxaliplatin, leucovorin and 5-FU.Then, patients receive placebo alone every day for 3 years total.
This Phase II SBIR grant is a follow-up to the Phase I SBIR grant "Computerized Screening for Comorbidity in Adolescents with Substance or Psychiatric Disorders." During Phase I, parent and adolescent self administered computerized versions of the psychiatric interview, the Kiddie Schedule for Affective Disorders and Schizophrenia (KSADS), were developed to assess DSM-IVR diagnoses in adolescents. Since the funding of the Phase I grant, there have been two significant developments in the field: the American Psychiatric Association's release of the DSM-5 manual, and NIMH's launch of the Research Domain Criteria (RDoC) initiative that aims to create the necessary database to derive a new psychiatric nomenclature informed by neuroscience, genetics, and psychology. The primary goals of Phase II include: 1) Update the parent and adolescent self-administered computerized KSADS (KSADS-COMP) so it is compatible with DSM-5 criteria; 2) Develop software for a clinician-administered computerized KSADS (KSADS-COMP); 3) Create a KSADS- Bridge product that includes a battery of RDoC computerized neurocognitive tasks that can be completed with the self- or clinician-administered KSADS-COMP; and 4) Examine the criterion, convergent, and discriminant validity of the self-administered KSADS-COMP, and the relationship among DSM-5 diagnoses, dimensional measures of psychopathology, and performance on RDoC neurocognitive tasks. Ultimately the aim of this initiative is to create an instrument that, in addition to providing a reliable comprehensive assessment tool for psychiatric disorders in adolescents, can bridge DSM-5 and RDoC diagnostic perspectives. A sample of 400 adolescents and their parents will be recruited for this study: half will complete the self-administered KSADS-COMP; the other half will complete the clinician-administered KSADSCOMP. All 400 adolescents and their parents, in addition to completing one of the KSADS-COMP versions, will also complete a battery of dimensional symptom rating scales. A subset of 210 adolescents and their parents will then complete the other version of the KSADS-COMP to test diagnostic concordance between the self- and clinician-administered KSADS-COMP. To obtain reliable Kappa estimates, this subset will include 30 adolescents with no psychopathology and 30 adolescents that meet criteria for each of the following diagnoses: conduct disorder, major depression, bipolar; substance use disorders; post traumatic stress disorder; and attention deficit hyperactivity disorder. This subset of 210 adolescents will also be administered the RDoC battery of neurocognitive computerized tasks. The KSADS-COMP and KSADS-Bridge assessment tools will have multiple clinical and research applications. In addition to helping identify comorbidity in teens with substance or psychiatric disorders, it will help to create the cross-talk needed between the DSM and RDoC diagnostic perspectives, and will help to improve clinical care in the short- and long-run as the field aims to transition to a new psychiatric nomenclature.
Families in the treatment group received one welcome visit, 12 visits from a community-based volunteer trained in the Sugira Muryango intervention over 3-4 months, as well as booster visits at 3 and 6 months. The primary caregiver, secondary caregiver if applicable, and any children ages 6-36 months participated in the sessions. Other family members were welcome to join as available.
The aim of this research was to perform a comparative clinical analysis of soft tissues in the area of soft tissue graft and collagen matrix transplantation. Thirty two patients diagnosed with partial absence of teeth was examined on the basis of the Department of Surgical Dentistry of the E.V. Borovsky Institute of Dentistry of I.M. Sechenov First Moscow State Medical University. Patients had a soft tissue thickness deficiency from the vestibular surface in the area of the planned dental implant placement in the distal parts of the mandible, which was an indication for its increase. All patients were randomly divided into two groups depending on method of soft tissue augmentation used. In 1 group (n=16) transplantation of a free connective tissue graft (CTG) from tuberosity area of the upper jaw was performed. In 2 group (n=16) collagen matrix "Fibro-Gide" was used. According to gender and age characteristics, both groups were comparable. Randomization of patients was carried out at the stage of surgical intervention as follows: after a dental implant placement and preparation of recipient's bed, an envelope with a randomly assigned treatment method (using a connective tissue graft or a collagen matrix) was opened.

During the operation, incision was made along the top of the alveolar ridge within the defect; a full-thickness muco-periosteal flap was elevated. Traditional 2-stage dental implantation was performed according to surgical protocols of dental implant systems Astra Tech (Dentsply Implants Manufacturing GmbH, Germany; registration in Russia 27.12.2019 No FSZ 2015/3214). A free connective tissue graft was harvested in patients of the first group. Graft was fixed with a horizontal U-shaped suture to the buccal muco-periosteal flap. In second patients group a fragment of the collagen matrix "Fibro-Gide" was fixed to the buccal muco-periosteal flap (Geistlich Pharma AG, Bahnhofstrasse 40, 6110 Wolhusen, Switzerland; registration in Russia 19.08.2020 No FSZ - 20207/11765). For patients of all groups mobilization of the muco-periosteal flap conducted followed by suturing the wound tightly without tension with simple interrupted sutures.

Postoperative recommendations included standard antibacterial and anti-inflammatory therapy in combination with the use of local antiseptics for daily care was prescribed.